EC-specific deletion of a single Pfkfb3 allele or administration of the PFKFB3 inhibitor (3-(3-pyridinyl)-1-(4-pyridynyl)-2-propen-1-one, 3PO) reduces tumor cell invasion and metastasis, normalizes tumor vessels, and improves the vascular barrier by reducing VE-cadherin (vascular endothelial cadherin) endocytosis [5]. Here, CDH5 is linked to neoplasm.